press center press release

NASDAQ OMX Welcomes Alimera Sciences to The NASDAQ Stock Market

Published

NEW YORK, April 26, 2010 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) the world's largest exchange company announced that the trading of Alimera Sciences commenced Thursday, April 22, 2010 on The NASDAQ Stock Market. Alimera Sciences trades under the ticker symbol (Nasdaq:ALIM).

"We are proud to welcome Alimera Sciences, a leading biopharmaceutical company specializing in prescription ophthalmic pharmaceuticals, to NASDAQ," said Bruce Aust, Executive Vice President, Corporate Client Group, NASDAQ OMX.

"Alimera joins 170 Biotech companies listed on The NASDAQ Stock Market, with a combined market value of $257.9 billion, more than any other exchange company," he added.

The NASDAQ OMX captured a total of 41 new listings in the first quarter of 2010, highlighted by a promising IPO market which brought 15 new companies to NASDAQ. The two largest domestic technology IPOs of the quarter chose to list on NASDAQ. SS&C Technologies (Nasdaq:SSNC), a leading provider of financial management software, and QuinStreet (Nasdaq:QNST), a leader in vertical marketing and media on the Internet, raised $160 million and $150 million, respectively.

About NASDAQ OMX

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries.  NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).

About Alimera Sciences:

 

The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO).

Cautionary Note Regarding Forward-Looking Statements

The matters described herein may contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to, factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Neither The NASDAQ OMX Group, Inc., nor any of its affiliates (collectively "NASDAQ OMX"), makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investors should undertake their own due diligence and carefully evaluate companies before investing.

NDAQG

CONTACT: The NASDAQ OMX Group, Inc. Media Contact: Jolene Libretto (646) 441-5220 Jolene.Libretto@nasdaqomx.com

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more